TLR9 and neoplasm: In light of the increased expression of PD-1 on tumor-infiltrating CD8 T cells and of PD-L1 on myeloid cells, we tested whether the combination of the TLR9 agonist with systemic administration of anti-PD-1 antibody would increase its therapeutic efficacy.